• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Diamyd Diabetes Vaccine Study gets Green Light to Resume by the FDA

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 15, 2022 at 11:22: PM
via Diamyd Medical is a well-known biotech company based in Sweden that is working to develop an antigen-specific immunotherapy called Diamyd for type 1 diabetes. In September 2021, the US Food and Drug Administration (FDA) issued a partial US clinical hold on the phase III DIAGNODE-3 clinical trial of the drug. The FDA stated then that it did not have enough information on questions about the antigen-specific immunotherapy. Several interactions between the company and the regulatory agency have been held since then to resolve the FDA’s questions.

article source
 




Top Bottom
Back
Quote